CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (LOSS) (UNAUDITED) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
REVENUE
Product sales	$ 19,625	$ 21,313	$ 38,837	$ 42,292
License and fee income	674	643	1,335	1,247
Revenue	20,299	21,956	40,172	43,539
COST OF SALES	12,530	13,942	25,378	26,916
GROSS PROFIT	7,769	8,014	14,794	16,623
OPERATING EXPENSES
Selling, general and administrative	6,141	5,378	11,819	11,279
Amortization of purchased intangibles	861	1,006	1,722	1,861
Research and development	272	312	552	589
Medical device excise tax	212		405
Restructuring	143		143
Loss on sale of equipment	9	3	5	3
Operating expenses	7,638	6,699	14,646	13,732
EARNINGS FROM OPERATIONS	131	1,315	148	2,891
OTHER INCOME (EXPENSE)
Interest income	24	36	51	74
Interest expense	(137)	(155)	(273)	(319)
Other	1	1	1	2
Other income (expense)	(112)	(118)	(221)	(243)
EARNINGS (LOSS) BEFORE INCOME TAXES	19	1,197	(73)	2,648
Income tax expense (benefit)	34	359	(24)	876
NET EARNINGS (LOSS)	(15)	838	(49)	1,772
EARNINGS PER SHARE:
Basic (in dollars per share)	$ 0.00	$ 0.02	$ 0.00	$ 0.05
Diluted (in dollars per share)	$ 0.00	$ 0.02	$ 0.00	$ 0.05
WEIGHTED AVERAGE SHARES:
Basic (in shares)	29,277	33,655	29,172	33,594
Diluted (in shares)	29,277	34,204	29,172	34,099
COMPREHENSIVE EARNINGS (LOSS)
Net earnings (loss)	(15)	838	(49)	1,772
Other comprehensive earnings (loss), net of taxes
Reclassification adjustment for gain included in net earnings		(1)		(1)
Unrealized gain (loss) on securities arising during the period	(22)	48	(22)	48
Total other comprehensive earnings (loss)	(22)	47	(22)	47
Total comprehensive earnings (loss)	$ (37)	$ 885	$ (71)	$ 1,819